Coronavirus (COVID-19) Collection
Could SARS-CoV-2-induced lung injury be attenuated by vitamin D?
A novel coronavirus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) had caused 4,761,559 confirmed cases and 317,529 confirmed deaths worldwide, as of May 20, 2020 ( https://www.who.int/emergencies/diseases/novel-coronavirus-2019 ). Many of the symptoms caused by SARS-CoV-2 are similar to those caused by severe acute respiratory syndrome coronavirus (SARS-CoV), especially acute respiratory distress syndrome (ARDS) (Li et al., 2020a). Previous studies have reported that ARDS is the primary cause of mortality and morbidity in intensive care units (ICUs) (Liu and Tan, 2020; Liu et al., 2020a, b).CORTICOSTEROIDS IN THE TREATMENT OF SEVERE COVID-19 LUNG DISEASE: THE PULMONOLOGY PERSPECTIVE FROM THE FIRST UNITED STATES EPICENTER
As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic first swept across the globe in the first quarter of 2020, the management of the associated clinical entity termed coronavirus disease 2019 (COVID-19) became the subject of institutional recommendations (Massachusetts General Hospital, 2020), societal guidelines (Bhimraj et al., 2020), and position statements (Russell et al, 2020). Because acute respiratory failure (ARF) in COVID-19 is triggered by a viral pathogen, it is understandable that the discussion of this potentially devastating illness has centered on its infectious disease and epidemiologic implications.
